Skip to main content

Live Zoster Vaccination Linked to Lower Risk for Cardiovascular Events

Medically reviewed by Carmen Pope, BPharm. Last updated on May 8, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, May 8, 2025 -- Live zoster vaccination is associated with a lower risk for overall cardiovascular events when compared with no vaccination, according to a study published online May 5 in the European Heart Journal.

Sooji Lee, from the Kyung Hee University Medical Center in Seoul, South Korea, and colleagues conducted a large-scale cohort study with long-term follow-up to examine the association between live zoster vaccination and the risk for various cardiovascular events. The risk for incident cardiovascular outcomes was assessed for individuals aged 50 years or older who had undergone live zoster vaccination versus unvaccinated individuals. After applying propensity score-based overlap weighting, data were included for 1,271,922 individuals, with a median follow-up of 6.0 years.

The researchers found associations for live zoster vaccination with lower risks for overall cardiovascular events (hazard ratio [HR], 0.77), especially major adverse cardiovascular events, heart failure, cerebrovascular disorders, ischemic heart disease, thrombotic disorders, and dysrhythmia (HRs, 0.74, 0.74, 0.76, 0.78, 0.78, and 0.79, respectively). The restricted mean survival time difference was 95.14 days per decade for overall cardiovascular events following live zoster vaccination. The protective association lasted for up to eight years, with the reduction greatest at two to three years postvaccination. Men, those aged younger than 60 years, those with unhealthy lifestyle habits, and those from low-income households and rural residents had a more pronounced decrease in cardiovascular disease risk.

"The findings suggest that implementing live zoster vaccination strategies may be associated with favorable cardiovascular outcomes across different population groups," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted May 2025

Read this next

Nirsevimab Effective for Reducing Burden of RSV in Infants

THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...

Real-Time AI-Driven Decision Support Aids Catheter Ablation

WEDNESDAY, May 7, 2025 -- An artificial intelligence (AI)-driven model can significantly improve procedural safety in cardiac electrophysiology with real-time decision support...

72 Percent of Infants Immunized Against Respiratory Syncytial Virus

TUESDAY, May 6, 2025 -- In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.